FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1977377005> ?p ?o ?g. }

• W1977377005 endingPage "460" @default.
• W1977377005 startingPage "452" @default.
• W1977377005 abstract "Study Objective. To evaluate the safety, effectiveness, and dosing of bivalirudin for treatment of heparin-induced thrombocytopenia (HIT) in critically ill patients with hepatic and/or renal dysfunction. Design. Retrospective cohort study. Setting. University-affiliated medical center Patients. Eighteen patients older than 18 years who were admitted to the intensive care unit (ICU), had hepatic and/or renal dysfunction, and were treated with bivalirudin for the diagnosis of HIT between January 1, 2004, and March 31, 2005. Measurements and Main Results. Patient records were reviewed for dosage and duration of bivalirudin therapy, occurrence of thrombosis, and clinically significant adverse effects. Of the 18 patients identified, 12 had both hepatic and renal dysfunction (group 1), four had hepatic dysfunction (group 2), and two had renal dysfunction (group 3). Demographics were similar among the groups. Mean ± SD age was 54 ± 15 years and weight was 82 ± 14 kg, 67% were male, 83% were Caucasian, and 56% were receiving renal replacement therapy. Mean bivalirudin doses were 0.06 ± 0.15 mg/kg/hour (median 0.03 mg/kg/hr), 0.14 ± 0.05 mg/kg/hour (median 0.14 mg/kg/hr), and 0.05 ± 0.01 mg/kg/hour (median 0.05 mg/kg/hr) for patients in groups 1, 2, and 3, respectively. Ten patients receiving continuous venovenous hemofiltration with or without dialysis received a mean dose of 0.04 ± 0.03 mg/kg/hour (median 0.03 mg/kg/hr). In the 18 patients, mean bivalirudin duration was 15 ± 17 days, activated partial thromboplastin time (aPTT) was 69 ± 22 seconds, and international normalized ratio was 2.2 ± 0.8. Supratherapeutic aPTTs were most common on days 1 (22%) and 2 (28%) when bivalirudin doses were highest. Clinically significant bleeding did not occur in any patient. Thrombosis occurred in one patient (6%) while receiving bivalirudin. Conclusion. Patients in the ICU who have hepatic and/or renal dysfunction require low doses of bivalirudin to achieve aPTT values 1.5–2.5 times baseline. Bivalirudin can be safely started at 0.14 mg/kg/hour in patients with hepatic dysfunction, 0.03–0.05 mg/kg/hour in those with renal or combined hepatic and renal dysfunction, and 0.03–0.04 mg/kg/hour in patients receiving continuous renal replacement therapy." @default.
• W1977377005 created "2016-06-24" @default.
• W1977377005 creator A5077824195 @default.
• W1977377005 creator A5082697782 @default.
• W1977377005 date "2006-04-01" @default.
• W1977377005 modified "2023-10-18" @default.
• W1977377005 title "Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction" @default.
• W1977377005 cites W1550111394 @default.
• W1977377005 cites W174314576 @default.
• W1977377005 cites W1977448641 @default.
• W1977377005 cites W1984138867 @default.
• W1977377005 cites W1984257251 @default.
• W1977377005 cites W2005018700 @default.
• W1977377005 cites W2005615751 @default.
• W1977377005 cites W2006731137 @default.
• W1977377005 cites W2006780952 @default.
• W1977377005 cites W2008996770 @default.
• W1977377005 cites W2012489492 @default.
• W1977377005 cites W2031283371 @default.
• W1977377005 cites W2043292703 @default.
• W1977377005 cites W2053515768 @default.
• W1977377005 cites W2070676143 @default.
• W1977377005 cites W2073637661 @default.
• W1977377005 cites W2082062489 @default.
• W1977377005 cites W2083884540 @default.
• W1977377005 cites W2109289067 @default.
• W1977377005 cites W2115535897 @default.
• W1977377005 cites W2126850862 @default.
• W1977377005 cites W2128318855 @default.
• W1977377005 cites W2150983644 @default.
• W1977377005 cites W2152393713 @default.
• W1977377005 cites W2316071283 @default.
• W1977377005 cites W2333983635 @default.
• W1977377005 cites W2558526329 @default.
• W1977377005 cites W3151469085 @default.
• W1977377005 cites W4240665535 @default.
• W1977377005 cites W4244417656 @default.
• W1977377005 cites W4293242440 @default.
• W1977377005 cites W4366507218 @default.
• W1977377005 doi "https://doi.org/10.1592/phco.26.4.452" @default.
• W1977377005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16553502" @default.
• W1977377005 hasPublicationYear "2006" @default.
• W1977377005 type Work @default.
• W1977377005 sameAs 1977377005 @default.
• W1977377005 citedByCount "88" @default.
• W1977377005 countsByYear W19773770052012 @default.
• W1977377005 countsByYear W19773770052013 @default.
• W1977377005 countsByYear W19773770052014 @default.
• W1977377005 countsByYear W19773770052015 @default.
• W1977377005 countsByYear W19773770052016 @default.
• W1977377005 countsByYear W19773770052017 @default.
• W1977377005 countsByYear W19773770052018 @default.
• W1977377005 countsByYear W19773770052019 @default.
• W1977377005 countsByYear W19773770052020 @default.
• W1977377005 countsByYear W19773770052022 @default.
• W1977377005 countsByYear W19773770052023 @default.
• W1977377005 crossrefType "journal-article" @default.
• W1977377005 hasAuthorship W1977377005A5077824195 @default.
• W1977377005 hasAuthorship W1977377005A5082697782 @default.
• W1977377005 hasConcept C126322002 @default.
• W1977377005 hasConcept C159641895 @default.
• W1977377005 hasConcept C167135981 @default.
• W1977377005 hasConcept C197934379 @default.
• W1977377005 hasConcept C2776376669 @default.
• W1977377005 hasConcept C2776472838 @default.
• W1977377005 hasConcept C2777288759 @default.
• W1977377005 hasConcept C2777557582 @default.
• W1977377005 hasConcept C2777565915 @default.
• W1977377005 hasConcept C2778063415 @default.
• W1977377005 hasConcept C2778261982 @default.
• W1977377005 hasConcept C2778865887 @default.
• W1977377005 hasConcept C2779541074 @default.
• W1977377005 hasConcept C2779978075 @default.
• W1977377005 hasConcept C2780400711 @default.
• W1977377005 hasConcept C42219234 @default.
• W1977377005 hasConcept C500558357 @default.
• W1977377005 hasConcept C71924100 @default.
• W1977377005 hasConcept C89560881 @default.
• W1977377005 hasConceptScore W1977377005C126322002 @default.
• W1977377005 hasConceptScore W1977377005C159641895 @default.
• W1977377005 hasConceptScore W1977377005C167135981 @default.
• W1977377005 hasConceptScore W1977377005C197934379 @default.
• W1977377005 hasConceptScore W1977377005C2776376669 @default.
• W1977377005 hasConceptScore W1977377005C2776472838 @default.
• W1977377005 hasConceptScore W1977377005C2777288759 @default.
• W1977377005 hasConceptScore W1977377005C2777557582 @default.
• W1977377005 hasConceptScore W1977377005C2777565915 @default.
• W1977377005 hasConceptScore W1977377005C2778063415 @default.
• W1977377005 hasConceptScore W1977377005C2778261982 @default.
• W1977377005 hasConceptScore W1977377005C2778865887 @default.
• W1977377005 hasConceptScore W1977377005C2779541074 @default.
• W1977377005 hasConceptScore W1977377005C2779978075 @default.
• W1977377005 hasConceptScore W1977377005C2780400711 @default.
• W1977377005 hasConceptScore W1977377005C42219234 @default.
• W1977377005 hasConceptScore W1977377005C500558357 @default.
• W1977377005 hasConceptScore W1977377005C71924100 @default.
• W1977377005 hasConceptScore W1977377005C89560881 @default.
• W1977377005 hasIssue "4" @default.

• next